poisar

Stocks · News reference

Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $120

BenzingaAug 20, 2026, 5:57 PMBenzinga Newsdesk

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $67 to $120.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 20, 2026, 5:57 PM
Checked
Aug 20, 2026, 5:57 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading